Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised PR Event in connection with the acquisition of the golf tournament Nordea Masters
Mandate

Vinge has advised PR Event in connection with the acquisition of the golf tournament Nordea Masters

September 27, 2013

Vinge has acted for PR Event i Båstad AB in connection with the acquisition of the golf tournament Nordea Masters by way of an asset transfer from Scandinavian Masters AB. PR Event is part of the Lagardère Unlimited Group, active within e.g. events production and management, marketing rights and  the talent representation business. Nordea Masters forms part of the European Tour and is with its 50 000 visitors per year Sweden’s largest recurring sports event. Closing of the transaction took place on 24 September 2013.

Partner Michael Wigge and associates Peter Sundgren and Sofie Bjärtun (M&A) acted for PR Event in connection with the transaction together with, among others, specialists Christian Hybbinette (Commercial Agreements) and Fredrik Gustafsson (Employment).    

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025